Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cineole→

Cineole Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
470-82-6
Molecular formula
C10H18O
Molecular weight
154.25 g/mol
Drug class
1,8-Cineole (eucalyptol)monoterpene oxide with mucolytic and anti-inflammatory properties
Mechanism of action
Modulates airway mucus secretion and may reduce inflammatory mediator production in respiratory mucosa. The relative contribution of secretolytic, mucolytic and anti-inflammatory actions depends on dose and formulation.
Indications / reported uses
  • Symptomatic relief of cough and mucus-related symptoms in selected respiratory conditions with authorised cineole products; this is the same active substance as eucalyptol and should not be assigned a separate salt- or name-based profile

Sources: NLM MeSH — 1,8-Cineole · PubMed — 1,8-Cineole respiratory clinical studies · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

1,8-Cineole (eucalyptol); monoterpene oxide with mucolytic and anti-inflammatory properties

Mechanism of action

Modulates airway mucus secretion and may reduce inflammatory mediator production in respiratory mucosa. The relative contribution of secretolytic, mucolytic and anti-inflammatory actions depends on dose and formulation.

General use cases

  • Symptomatic relief of cough and mucus-related symptoms in selected respiratory conditions with authorised cineole products; this is the same active substance as eucalyptol and should not be assigned a separate salt- or name-based profile

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Cineole Environmental Risk Assessment (ERA) (the Cineole ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.